✦ LIBER ✦

Phase II study of intraperitoneal cisplatin plus systemic etoposide as second-line treatment in patients with small volume residual ovarian cancer

✍ Scribed by R.S. de Jong; P.H.B. Willemse; H. Boonstra; E.G.E. de Vries; W.T.A. van der Graaf; D.Th. Sleijfer; A.G.J. van der Zee; N.H. Mulder

Book ID: 116166174
Publisher: Elsevier Science
Year: 1995
Tongue: English
Weight: 634 KB
Volume: 31
Category: Article
ISSN: 0959-8049
DOI: 10.1016/0959-8049(94)00516-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Intraperitoneal High-Dose Cisplatin and

Intraperitoneal High-Dose Cisplatin and Etoposide with Systemic Thiosulfate Protection in Second-Line Treatment of Advanced Ovarian Cancer

✍ Henric Malmström; Svein Rasmussen; Ernst Simonsen 📂 Article 📅 1993 🏛 Elsevier Science 🌐 English ⚖ 328 KB

Intraperitoneal high-dose cisplatin and

Intraperitoneal high-dose cisplatin and etoposide with systemic thiosulfate protection in second-line treatment of advanced ovarian cancer

✍ H. Malmstrom; S. Rasmussen; E. Simonsen 📂 Article 📅 1994 🏛 Elsevier Science 🌐 English ⚖ 259 KB

Phase I/II study of oral etoposide plus

Phase I/II study of oral etoposide plus GM-CSF as second-line chemotherapy in platinum-pretreated patients with advanced ovarian cancer

✍ Baur, M; Schernhammer, E; Gneist, M; Sevelda, P; Speiser, P; Hudec, M; Dittrich, 📂 Article 📅 2005 🏛 Nature Publishing Group 🌐 English ⚖ 109 KB

A phase II study of etoposide combined w

A phase II study of etoposide combined with ifosfamide as second-line therapy in cisplatin-resistant ovarian carcinomas

✍ Claes Tropé; Janne Kærn; Ignace Vergote; Svein Vossli 📂 Article 📅 1990 🏛 Springer 🌐 English ⚖ 246 KB

Gemcitabine combined with cisplatin as f

Gemcitabine combined with cisplatin as first-line treatment in patients with epithelial ovarian cancer: a phase II study

✍ D Belpomme; I Krakowski; M Beauduin; T Petit; J.L Canon; J Janssens; S Gauthier; 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 111 KB

A multicenter, randomized, Phase II stud

A multicenter, randomized, Phase II study of cisplatin, etoposide, and gemcitabine or cisplatin plus gemcitabine as first-line treatment in patients with poor-prognosis small cell lung carcinoma

✍ Filippo De Marinis; Fabrizio Nelli; Marco Lombardo; Francesco Ferraú; Santi Barb 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 122 KB 👁 1 views

## Abstract ## BACKGROUND The objective of this study was to evaluate the activity and toxicity of combined cisplatin, etoposide, and gemcitabine (PEG) and combined cisplatin plus gemcitabine (PG) in previously untreated patients with extensive‐stage and poor‐prognosis limited‐stage small‐cell lun